Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2019 - 2026)

Quantum Biopharma has disclosed Income from Non-Controlling Interests across 8 years of filings, most recently posting -$13.8 million for Q1 2026.

• Income from Non-Controlling Interests for Q1 2026 came in at -$13.8 million, down 257.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 212.28% YoY), and the FY2025 annual result was -$27.0 million, down 80.73% from the prior year.
• Income from Non-Controlling Interests came in at -$13.8 million for Q1 2026 at Quantum Biopharma, down from -$3.7 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $25.4 million in Q2 2023 to a low of -$34.8 million in Q4 2023.
• The 5-year median for Income from Non-Controlling Interests is -$1.6 million (2023), against an average of -$1.2 million.
• Across the five-year window, Income from Non-Controlling Interests tumbled 268.62% in 2023 and jumped 517.89% in 2025, its largest moves.
• Quantum Biopharma's Income from Non-Controlling Interests stood at $5.9 million in 2022, then tumbled by 689.46% to -$34.8 million in 2023, then surged by 84.33% to -$5.5 million in 2024, then surged by 32.13% to -$3.7 million in 2025, then tumbled by 271.41% to -$13.8 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at -$13.8 million (Q1 2026), -$3.7 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.